Skip to main content
Equibles
WAT logo

WAT · Waters Corp /De/

Track WAT — free

Use WAT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$414.69 -6.57 (-1.56%) At close · Aug 28
S&P 500 member Russell 1000 member Rebalance outlook locked
Customer concentration — top customer 10% of receivables

One customer — 10% of receivables (the period ended July 4, 2026)

“The Company considers the $673 million classified in Accounts receivable, net to be a significant concentration of receivables, as it accounts for greater than 10 % of the Company’s total accounts receivable balance for the period ended July 4, 2026.”
View the 10-Q filed Aug 11, 2026
Market Cap
$40.74B
Shares
98.25M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$414.69 Open$417.80 Day$412.38–422.50 52W close$283.32–421.26 Avg vol 30d863K Short int3.6M · 3.7% float · 3.9d Short vol56% Last earningsAug 4, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 11

Up next

Next earnings call
Oct 30, 2026 Est · unconfirmed · in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 11, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Moderate
      Market backdrop VIX 14.4 · calm Equity put/call 0.62
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +15%
      above
      Price vs 50-day avg +7%
      above
      RSI (14) 59
      neutral
      MACD trend Negative
      52-week position 95%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +10%
      trailing
      6-month return +36%
      trailing
      YTD return +9%
      this year
      Relative strength +22%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $387 › 200d $360 — 50d above 200d
      Institutional flow Distributing
      -0% holders QoQ · +158 funds added
      Insider flow Distributing
      Net -$1.4M over 90 days · 100% sells
      Short interest Falling
      3.70% of float · ▼ -12.7% MoM · 3.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      1,178 holders — near 3-yr high, broad support
      Squeeze score 56
      elevated · 0–100
      Fundamentals
      Fair
      Revenue growth +7%
      Y/Y
      Gross margin 38%
      contracting
      EPS growth +0%
      Y/Y
      Buyback $1.0B
      remaining
      Balance sheet $819.0M
      net debt
      Quant / Vol
      risk profile
      Moderate
      Volatility 36%
      annualized · 1-yr
      Max drawdown −31%
      past year
      ATR 2.9%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 1 of last 4
      Latest guidance · from the 8-K filed Aug 4, 2026
      full-year 2026
      Organic constant currency revenue growth Non-GAAP Raised 7% – 9%
      May 5, 2026 6.5% – 8% changed to Aug 4, 2026 7% – 9%
      Organic reported revenue Initiated $3.37B – $3.43B
      Total Company reported revenue Initiated $6.42B – $6.48B
      prior FY $3.17B midpoint +103.6% Y/Y
      Adjusted EPS Non-GAAP Initiated $14.45 – $14.65
      third quarter 2026
      Organic reported revenue Initiated $850M – $867M
      Acquired business reported revenue Initiated $895M
      Total Company reported revenue Initiated $1.75B – $1.76B
      prior qtr $1.65B midpoint +6.6% QoQ
      Adjusted EPS Non-GAAP Initiated $3.95 – $4.05
      Prior guidance period ended · from the 8-K filed May 5, 2026
      Total Company reported revenue · second quarter 2026 $1.62B – $1.63B
      Organic reported revenue · second quarter 2026 $814M – $829M
      Acquired business reported revenue · second quarter 2026 $802M
      Adjusted EPS · second quarter 2026 $2.95 – $3.05
      Organic constant currency revenue growth · second quarter 2026 6% – 8%
      Guided vs delivered · last 4 settled
      Total Company reported revenue second quarter 2026
      guided $1.62B – $1.63B
      $1.65B Beat +1.3%
      GAAP earnings per diluted share Full-Year 2025
      guided $11.45 – $11.55
      $10.76 Miss −6.4%
      GAAP earnings per diluted share Third Quarter 2025
      guided $2.70 – $2.80
      $2.50 Miss −9.1%
      Full-year EPS full year
      guided $12.20 – $12.30
      $10.84 Miss −11.5%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +15% Bullish
      Price vs 50-day avg
      +7% Bullish
      RSI (14)
      59 Neutral
      MACD trend
      Negative Bearish
      52-week position
      95% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $387 › 200d $360 — 50d above 200d
      Institutional flow Distributing
      -0% holders QoQ · +158 funds added
      Insider flow Distributing
      Net -$1.4M over 90 days · 100% sells
      Short interest Falling
      3.70% of float · ▼ -12.7% MoM · 3.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      1,178 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $283 Now $415 · 95% Range high $421
      vs 200-day avg +15% vs 50-day avg +7%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Advanced Diagnostics Division (ADx) Clinical Business Unit reported revenue 72M Q2 2026 —
      Advanced Diagnostics Division (ADx) Diagnostic Solutions reported revenue 449M Q2 2026 —
      Analytical Sciences Division (ASD) reported revenue 669M Q2 2026 —
      Biosciences and Diagnostic Solutions revenue 817M Q2 2026 —
      Biosciences Division (WBD) reported revenue 368M Q2 2026 —
      Materials Sciences Division (MSD) reported revenue 87M Q2 2026 —
      Organic revenue non-GAAP 828M Q2 2026 —
      Adjusted Non-GAAP Diluted Earnings Per Share non-GAAP $2.7 Three Months Ended April 4, 2026 —
      Adjusted Non-GAAP Net Income non-GAAP $222M Three Months Ended April 4, 2026 —
      Adjusted Non-GAAP Operating Income non-GAAP $300M Three Months Ended April 4, 2026 —
      Adjusted Non-GAAP Operating Income Percentage non-GAAP 23.6% Three Months Ended April 4, 2026 —
      Currency Translation Impact non-GAAP 2% Three Months Ended April 4, 2026 —
      Free Cash Flow - Adjusted Non-GAAP non-GAAP -$42M Three Months Ended April 4, 2026 —
      Organic Reported Revenue Growth non-GAAP 13% Three Months Ended April 4, 2026 —
      non-GAAP EPS non-GAAP $13.13 Full-Year 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Diagnostics & Research — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      WAT
      Waters Corp /De/
      this stock
      		$40.74B +9.2% +7.0% — 3.7%
      TMO
      Thermo Fisher Scientific Inc.
      		 $230.05B +7.4% +14.5% 33.5 1.3%
      DHR
      Danaher Corp /De/
      		 $151.89B -5.6% +8.5% 38.3 1.2%
      NTRA
      Natera, Inc.
      		 $48.82B +42.4% -2.8% — 3.0%
      IDXX
      Idexx Laboratories Inc /De
      		 $43.72B -18.0% +10.4% 39.0 2.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      1,178
      % held
      100.1%
      Net QoQ
      +3.2M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      910
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      3.6M
      Days to cover
      3.9d
      Change
      -531.1K sh
      View
      Short Volume
      Short vol %
      56%
      As of
      Aug 28, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      8.2K
      Value
      $3.1M
      As of
      Jul 17, 2026
      View
      Off-Exchange
      Off-exchange %
      46.4%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$1.4M
      Buyers / Sellers
      0 / 1
      Buyers Sellers
      View
      Congressional Trades Buy
      Member
      Gilbert Cisneros
      Amount
      $1.0K–$15.0K
      Traded
      Mar 18, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $3.2B
      Net income (FY)
      $642.6M
      EPS diluted
      $10.76
      View
      Buybacks
      Authorized
      $4.8B
      Remaining
      $1.0B
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 21, 2026
      This year
      15
      View
      Proposed Sales
      Value
      $1.4M
      Shares
      3.6K
      Filed
      Aug 6, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 4, 2026
      View
      Investor Relations
      Latest news
      Waters Launches Industry's Most S…
      Published
      Jul 27, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      WAT +1.0% +9.9% +35.7% +9.9% +9.2%
      SPY +0.5% +3.0% +13.4% +3.0% +12.8%
      vs SPY +0.5% +6.9% +22.2% +6.9% -3.6%

      Capital returns

      Buyback program · as of Jul 4, 2026
      Authorized
      $4.80B
      Spent (derived)
      $3.80B
      Remaining
      $1.00B
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1000697 CUSIP 941848103 13F (30d) 798 filings 752 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)